Trials / Completed
CompletedNCT04966195
Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Macrovascular invasion (MVI) is common in HCC, Portal vein tumor thrombus (PVTT) is the most common form of MVI in HCC, with an incidence ranging from 44 to 62.2%. About 10% to 60% of HCC patients have PVTT at the time of diagnosis. the prognosis for those with PVTT remains poor, as their median survival is only 2-4 months via supportive care. There is currently no widely-accepted consensus for the management of HCC with PVTT. According to some guidelines in Europe and America, HCC with PVTT is regarded as Stage C per Barcelona Clinic Liver Cancer (BCLC) Staging system, and sorafenib alone is recommended as the treatment of choice. This study is to analyze the safety and efficacy of radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | stereotactic body raiotherapy | stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-06-30
- Completion
- 2018-08-30
- First posted
- 2021-07-19
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04966195. Inclusion in this directory is not an endorsement.